Does Rallies show Form 4 insider transactions for CBIO?

Yes. Rallies tracks CBIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CBIO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CBIO. It does not provide personalized investment advice.

CBIO (Crescent Biopharma, Inc. Common Stock) Stock Analysis - Insider Trades

Crescent Biopharma, Inc. Common Stock (CBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, CBIO trades at $18.91 with a market cap of $511.51M and a P/E ratio of -243.63. CBIO moved +3.63% today. Year to date, CBIO is +70.21%; over the trailing twelve months it is flat. Its 52-week range spans $8.72 to $27.41. Analyst consensus is strong buy with an average price target of $29.50. Rallies surfaces CBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CBIO stock inside the company?

Recent CBIO insider activity includes Fairmount Funds Management LLC bought 1.36M, USMAN NASSIM bought 3.25K, Miller Seline E. bought 3.25K, Blouse Grant E. bought 3.25K, and USMAN NASSIM bought 3.25K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CBIO Key Metrics

Key financial metrics for CBIO
Metric	Value
Price	$18.91
Market Cap	$511.51M
P/E Ratio	-243.63
EPS	$-0.08
Dividend Yield	0.00%
52-Week High	$27.41
52-Week Low	$8.72
Volume	0
Avg Volume	0
Revenue (TTM)	$117.05M
Net Income	$-1.39M
Gross Margin	95.09%

Recent CBIO Insider Trades

Fairmount Funds Management LLC bought 1.36M (~$18.24M) on Dec 4, 2025.
USMAN NASSIM bought 3.25K (~$1.53K) on Aug 9, 2022.
Miller Seline E. bought 3.25K (~$1.53K) on Aug 9, 2022.
Blouse Grant E. bought 3.25K (~$1.53K) on Aug 9, 2022.
USMAN NASSIM bought 3.25K (~$1.50K) on Feb 9, 2022.

Latest CBIO News

Crescent Biopharma Ends Q1 with $189.2M Cash, $1M Revenue; ADC Combo Trial in H2 2026 — Apr 29, 2026
Crescent Biopharma Grants 12,525 Share Options at $25.70 Strike Price — Apr 24, 2026
Crescent Biopharma Posts -74.58% ROIC Versus 9.98% WACC — Mar 5, 2026
Crescent Biopharma Secures $185M, Launches CR-001 Phase 1/2 Trial with Kelun-Biotech Partnership — Feb 26, 2026
Crescent Biopharma Grants 24,600 Options at $9.33 Exercise Price — Feb 19, 2026

CBIO Analyst Consensus

7 analysts cover CBIO: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $29.50.

Common questions about CBIO

Who is trading CBIO stock inside the company?: Recent CBIO insider activity includes Fairmount Funds Management LLC bought 1.36M, USMAN NASSIM bought 3.25K, Miller Seline E. bought 3.25K, Blouse Grant E. bought 3.25K, and USMAN NASSIM bought 3.25K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CBIO?: Yes. Rallies tracks CBIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CBIO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CBIO. It does not provide personalized investment advice.